文献速递中药与中成药合理使用中医内科

金红汤与亚胺培南/西司他丁经OATs介导的益药相互作用:大黄酸的作用

Beneficial herb-drug interaction of rhein in Jinhongtang and Imipenem/Cilastatin mediated by organic anion transporters.
PubMed 文献 · J Ethnopharmacol · 2023-04-05

本研究探讨金红汤增强亚胺培南/西司他丁抗菌活性的机制。在金黄色葡萄球菌脓毒症小鼠模型中,金红汤联用提高生存率、降低细菌载量和炎症,但体外MIC/MBC不变;大鼠药动学显示金红汤使亚胺培南清除率降低58.5%、半衰期延长约1.2倍,并抑制OAT1/3介导的摄取,其中大黄酸抑制最强(IC50 0.08±0.01 μM对OAT1,2.86±0.28 μM对OAT3)。

要点

  • 金红汤联用亚胺培南/西司他丁可增强脓毒症小鼠抗菌活性
  • 机制为抑制OATs减少亚胺培南肾排泄,并非直接抗菌
  • 大黄酸是金红汤中抑制OAT1/3最强的成分

核心结论

  • 金红汤通过抑制OATs减少亚胺培南肾排泄,增强亚胺培南/西司他丁对金黄色葡萄球菌脓毒症小鼠的抗菌活性。

研究设计与样本

  • 采用金黄色葡萄球菌诱导的脓毒症小鼠模型评价体内药效互动,体外测定MIC和MBC,大鼠药动学研究及OAT1/3-HEK293细胞摄取实验,并用UHPLC-Q-TOF-MS鉴定入血成分。

主要发现

  • 与单用亚胺培南/西司他丁相比,联用金红汤的小鼠生存率更高、血液和肺组织细菌载量更低、炎症更轻。
  • 体外金红汤未显著改变亚胺培南/西司他丁对金黄色葡萄球菌的MIC和MBC。
  • 大鼠联用金红汤后亚胺培南血浆浓度升高、尿排泄减少,CLr降低58.5%,t1/2延长约1.2倍。
  • 金红汤提取物、单味药及主要可吸收成分不同程度抑制OAT1/3-HEK293细胞对探针底物和亚胺培南的摄取,大黄酸抑制最强,IC50为0.08±0.01 μM(OAT1)和2.86±0.28 μM(OAT3)。
  • 联用大黄酸也显著增强亚胺培南/西司他丁在脓毒症小鼠中的抗菌活性。

关键数值与推荐

  • 亚胺培南CLr降低58.5%,t1/2延长约1.2倍(大鼠联用金红汤)。
  • 大黄酸抑制OAT1的IC50为0.08±0.01 μM,抑制OAT3的IC50为2.86±0.28 μM。

临床怎么用

  • 金红汤可作为增强亚胺培南/西司他丁抗菌活性的辅助用药,但需关注OATs介导的草药-药物相互作用可能影响亚胺培南药动学。

局限性

  • 研究基于小鼠和大鼠及细胞模型,尚未在临床患者中验证。
  • 金红汤成分复杂,其他成分对OATs及亚胺培南处置的贡献未完全阐明。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ETHNOPHARMACOLOGICAL RELEVANCE: Jinhongtang as a traditional Chinese medicine (TCM) formula, has been widely used as a clinical adjuvant in the treatment of acute abdominal diseases and sepsis. Clinical benefits of the concurrent use of Jinhongtang and antibiotics have been observed, however, the mechanism has not been fully understood. AIM OF THE STUDY: The present study aimed to explore the effect of Jinhongtang on the antibacterial activity of Imipenem/Cilastatin and to clarify the underlying mechanism of herb-drug interaction (HDI). MATERIALS AND METHODS: A mouse model of sepsis induced by Staphylococcus aureus (S. aureus) was used to evaluate the pharmacodynamic interaction in vivo. In vitro antibacterial activity of Imipenem/Cilastatin was studied by determining minimal inhibitory concentration (MIC) and minimal bactericidal concentration (MBC). Pharmacokinetic interaction was investigated by pharmacokinetic studies in rats and uptake assays using OAT1/3-HEK293 cells. The main constituents ingested into blood of rats were qualitatively identified by UHPLC-Q-TOF-MS. RESULTS: Mice treated by Imipenem/Cilastatin and Jinhongtang exhibited higher survival rate, lower bacteria load and less inflammation in blood and lung tissues, compared with those treated by Imipenem/Cilastatin alone after injection of S. aureus. However, MIC and MBC of Imipenem/Cilastatin against S. aureus in vitro were not significantly changed in the presence of Jinhongtang. On the contrary, Jinhongtang increased the plasma concentration of Imipenem and decreased its urinary excretion in rats. CLr of Imipenem was reduced by 58.5%, while its half-life (t1/2) was prolonged for approximate 1.2 times after coadministered Jinhongtang. Furthermore, the extracts of Jinhongtang, single herb in the prescription, and main absorbable constituents inhibited cellular uptake of probe substrates and Imipenem by OAT1/3-HEK293 cells to different extents. Among them, rhein exhibited the strongest inhibition capacity with IC50 values of 0.08 ± 0.01 μM (OAT1) and 2.86 ± 0.28 μM (OAT3). Moreover, coadministration of rhein also significantly enhanced the antibacterial activity of Imipenem/Cilastatin in sepsis mice. CONCLUSION: Concomitant administration of Jinhongtang enhanced antibacterial activity of Imipenem/Cilastatin in sepsis mice induced by S. aureus through reducing renal elimination of Imipenem via inhibition of OATs. Our investigation provided the insight of Jinhongtang as an effective supplement to enhance the antibacterial activity of Imipenem/Cilastatin and can be useful for future clinical studies.

来源:J Ethnopharmacol,查看原文。版权归原作者所有。

引用

  1. Wu F, Zhao T, Zhang Y, et al. Beneficial herb-drug interaction of rhein in Jinhongtang and Imipenem/Cilastatin mediated by organic anion transporters. J Ethnopharmacol. 2023. PMID: 37023835. doi:10.1016/j.jep.2023.116449

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。